KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.

Fatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, Heather McArthur, Peter Schmid, Javier Cortes, Nadia Harbeck, Melinda L Telli, David W Cescon, Peter A Fasching, Zhimin Shao, Delphine Loirat, Yeon Hee Park, Manuel Gonzalez Fernandez, Gábor Rubovszky, Laura Spring, Seock-Ah Im, Rina Hui, Toshimi Takano, Fabrice André, Hiroyuki Yasojima, Yu Ding, Liyi Jia, Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia

Nat Med 31(2) 442-448

PMID39838117
PMCIDPMC11835712
DOI10.1038/s41591-024-03415-7
发表日期2025-01-21
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:森林图/亚组分析图;Fig. 3:AI 判定为 other;Extended Data Fig. 1:AI 判定为 forest plot;Extended Data Fig. 2:AI 判定为 flow diagram。
摘要

摘要

Addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition of neoadjuvant pembrolizumab to chemotherapy would improve outcomes in high-risk, early-stage, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer remains unclear. We conducted a double-blind, placebo-controlled phase 3 study (KEYNOTE-756) in which patients with previously untreated ER+/HER2- grade 3 high-risk invasive breast cancer (T1c-2 (≥2 cm), cN1-2 or T3-4, cN0-2) were randomly assigned (1:1) to neoadjuvant pembrolizumab 200 mg or placebo Q3W given with paclitaxel QW for 12 weeks, followed by four cycles of doxorubicin or epirubicin plus cyclophosphamide Q2W or Q3W. After surgery (with/without adjuvant radiation therapy), patients received adjuvant pembrolizumab or placebo for nine cycles plus adjuvant endocrine therapy. Dual primary endpoints were pathological complete response and event-free survival in the intention-to-treat population. In total, 635 patients were assigned to the pembrolizumab-chemotherapy arm and 643 to the placebo-chemotherapy arm. At the study's prespecified first interim analysis, the pathological complete response rate was 24.3% (95% confidence interval (CI), 21.0-27.8%) in the pembrolizumab-chemotherapy arm and 15.6% (95% CI, 12.8-18.6%) in the placebo-chemotherapy arm (estimated treatment difference, 8.5 percentage points; 95% CI, 4.2-12.8; P = 0.00005). Event-free survival was not mature in this analysis. During the neoadjuvant phase, treatment-related adverse events of grade ≥3 were reported in 52.5% and 46.4% of patients in the pembrolizumab-chemotherapy and placebo-chemotherapy arms, respectively. In summary, the addition of pembrolizumab to neoadjuvant chemotherapy significantly improved the pathological complete response rate in patients with high-risk, early-stage ER+/HER2- breast cancer. Safety was consistent with the known profiles of each study treatment. Follow-up continues for event-free survival. ClinicalTrials.gov identifier: NCT03725059 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Disposition of patients in the study. Progressive disease included radiographic progressive disease. Patients did not have to complete all neoadjuvant therapy to undergo surgery.
非 KM Figure
Fig. 2Fig. 2. Subgroup analysis of the difference in percentages of patients with a pCR at the first interim analysis. Data from key subgroups are shown. For the overall population, the estimated mean treatment difference with 95% CI was calculated using the stratified Miettinen–Nurminen method. The analysis for PD-L1 CPS subgroups was stratified. All other analyses were unstratified. The footnote ‘a’ indicates the subgroup analyses of pCR based on a PD-L1 CPS cutoff of 20 were not prespecified. PD-L1 CPS was defined as the number of PD-L1-positive tumor cells, lymphocytes and macrophages divided by the total number of tumor cells multiplied by 100. ECOG performance status ranges from 0 to 5, with higher scores indicating greater disability.
非 KM Figure
Fig. 3Fig. 3. RCB at the first interim analysis. RCB was an exploratory endpoint and was assessed by a local pathologist at the time of surgery. RCB-0, RCB-1, RCB-2 and RCB-3 denote increasingly larger residual diseases. RCB data were missing for 24 (3.8%) and 14 patients (2.2%) in the pembrolizumab‒chemotherapy and placebo‒chemotherapy arms, respectively.
非 KM Figure
Extended Data Fig. 1Extended Data Fig. 1. Post hoc exploratory analysis of the difference in percentages of patients with a pathological complete response by estrogen receptor positivity and PD-L1 combined positive score at the first interim analysis. Programmed cell death ligand 1 (PD-L1) combined positive score (CPS) was defined as the number of PD-L1-positive tumor cells, lymphocytes and macrophages divided by the total number of tumor cells multiplied by 100. No pathological complete response occurred in patients with tumor PD-L1 CPS < 1 with estrogen receptor (ER) positivity < 10% (pembrolizumab arm, n = 1; placebo arm, n = 4). For the overall population, the estimated treatment difference was calculated using the Miettinen–Nurminen method stratified by region (China vs Eastern Europe vs all other countries) and PD-L1 status (CPS ≥ 1 vs < 1). Estimated treatment differences for other endpoints were based on the Miettinen–Nurminen method (unstratified).
非 KM Figure
Extended Data Fig. 2Extended Data Fig. 2. Multiplicity graph for type I error control of study hypotheses. The prespecified analysis plan allows alpha passing from successful endpoint(s) to other(s). H, hypothesis.
非 KM Figure